The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Top Cited Papers
- 10 June 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Microbiology
- Vol. 11 (7), 482-496
- https://doi.org/10.1038/nrmicro3046
Abstract
International audienceThe availability of the first molecular clone of the hepatitis C virus (HCV) genome allowed the identification and biochemical characterization of two viral enzymes that are targets for antiviral therapy: the protease NS3-4A and the RNA-dependent RNA polymerase NS5B. With the advent of cell culture systems that can recapitulate either the intracellular steps of the viral replication cycle or the complete cycle, additional drug targets have been identified, most notably the phosphoprotein NS5A, but also host cell factors that promote viral replication, such as cyclophilin A. Here, we review insights into the structures of these proteins and the mechanisms by which they contribute to the HCV replication cycle, and discuss how these insights have facilitated the development of new, directly acting antiviral compounds that have started to enter the clinicThis publication has 128 references indexed in Scilit:
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1The New England Journal of Medicine, 2012
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2011
- Recruitment and Activation of a Lipid Kinase by Hepatitis C Virus NS5A Is Essential for Integrity of the Membranous Replication CompartmentCell Host & Microbe, 2011
- microRNA-122 stimulates translation of hepatitis C virus RNAThe EMBO Journal, 2008
- Position-Dependent Function for a Tandem MicroRNA miR-122-Binding Site Located in the Hepatitis C Virus RNA GenomeCell Host & Microbe, 2008
- Hepatitis C virus infection protein networkMolecular Systems Biology, 2008
- Cellular cofactors affecting hepatitis C virus infection and replicationProceedings of the National Academy of Sciences of the United States of America, 2007
- Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteinsProceedings of the National Academy of Sciences of the United States of America, 2007
- Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virusNature, 2005
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005